United Therapeutics will license, develop, and commercialize CollPlant Holdings’ recombinant human collagen (rhCollagen) and BioInk technology for 3D bioprinting of solid-organ scaffolds for human transplants, the companies said today, through a collaboration that could generate more than $44 million.
{iframe}https://www.genengnews.com/gen-news-highlights/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants/81256351/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20181022&oly_enc_id=5901d8426578g1y&ajs_trait_oebid=9675b9130356b7s{/iframe}